Proton pump inhibitor use increases the risk of peritonitis in peritoneal dialysis patients.
Peritonitis is a major and the most significant complication of peritoneal dialysis (PD). Although some predictors of peritonitis in PD patients are known, the association between proton pump inhibitor (PPI) use and peritonitis has not been characterized. Here, we examined whether PPI use is a risk...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2019-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0224859 |
| _version_ | 1818833296626286592 |
|---|---|
| author | Sayaka Maeda Makoto Yamaguchi Kunihiro Maeda Naoto Kobayashi Naoki Izumi Masaaki Nagai Takaaki Obayashi Wataru Ohashi Takayuki Katsuno Hironobu Nobata Yasuhiko Ito |
| author_facet | Sayaka Maeda Makoto Yamaguchi Kunihiro Maeda Naoto Kobayashi Naoki Izumi Masaaki Nagai Takaaki Obayashi Wataru Ohashi Takayuki Katsuno Hironobu Nobata Yasuhiko Ito |
| author_sort | Sayaka Maeda |
| collection | DOAJ |
| description | Peritonitis is a major and the most significant complication of peritoneal dialysis (PD). Although some predictors of peritonitis in PD patients are known, the association between proton pump inhibitor (PPI) use and peritonitis has not been characterized. Here, we examined whether PPI use is a risk factor for the development of peritonitis, based on a single-center retrospective analysis of 230 consecutive Japanese PD patients at Narita Memorial Hospital. We assessed the association between PPI use and subsequent first episode of peritonitis using multivariate Cox proportional hazards models, following adjustment for clinically relevant factors. The median follow-up period was 36 months (interquartile range, 19-57 months). In total, 86 patients (37.4%) developed peritonitis. Analysis with multivariate Cox proportional hazards models revealed the following significant predictors of peritonitis: PPI use (adjusted hazard ratio [HR] = 1.72, 95% confidence interval [CI]: 1.11-2.66; P = 0.016) and low serum albumin level (per g/dl adjusted HR = 0.59, 95% CI: 0.39-0.90; P = 0.014). Thus, PPI use was independently associated with PD-related peritonitis. The results suggest that nephrology physicians should exercise caution when prescribing PPIs for PD patients. |
| first_indexed | 2024-12-19T02:16:40Z |
| format | Article |
| id | doaj.art-d27aceda4e9f4bb7ae39af7ba854375b |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-19T02:16:40Z |
| publishDate | 2019-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-d27aceda4e9f4bb7ae39af7ba854375b2022-12-21T20:40:23ZengPublic Library of Science (PLoS)PLoS ONE1932-62032019-01-011411e022485910.1371/journal.pone.0224859Proton pump inhibitor use increases the risk of peritonitis in peritoneal dialysis patients.Sayaka MaedaMakoto YamaguchiKunihiro MaedaNaoto KobayashiNaoki IzumiMasaaki NagaiTakaaki ObayashiWataru OhashiTakayuki KatsunoHironobu NobataYasuhiko ItoPeritonitis is a major and the most significant complication of peritoneal dialysis (PD). Although some predictors of peritonitis in PD patients are known, the association between proton pump inhibitor (PPI) use and peritonitis has not been characterized. Here, we examined whether PPI use is a risk factor for the development of peritonitis, based on a single-center retrospective analysis of 230 consecutive Japanese PD patients at Narita Memorial Hospital. We assessed the association between PPI use and subsequent first episode of peritonitis using multivariate Cox proportional hazards models, following adjustment for clinically relevant factors. The median follow-up period was 36 months (interquartile range, 19-57 months). In total, 86 patients (37.4%) developed peritonitis. Analysis with multivariate Cox proportional hazards models revealed the following significant predictors of peritonitis: PPI use (adjusted hazard ratio [HR] = 1.72, 95% confidence interval [CI]: 1.11-2.66; P = 0.016) and low serum albumin level (per g/dl adjusted HR = 0.59, 95% CI: 0.39-0.90; P = 0.014). Thus, PPI use was independently associated with PD-related peritonitis. The results suggest that nephrology physicians should exercise caution when prescribing PPIs for PD patients.https://doi.org/10.1371/journal.pone.0224859 |
| spellingShingle | Sayaka Maeda Makoto Yamaguchi Kunihiro Maeda Naoto Kobayashi Naoki Izumi Masaaki Nagai Takaaki Obayashi Wataru Ohashi Takayuki Katsuno Hironobu Nobata Yasuhiko Ito Proton pump inhibitor use increases the risk of peritonitis in peritoneal dialysis patients. PLoS ONE |
| title | Proton pump inhibitor use increases the risk of peritonitis in peritoneal dialysis patients. |
| title_full | Proton pump inhibitor use increases the risk of peritonitis in peritoneal dialysis patients. |
| title_fullStr | Proton pump inhibitor use increases the risk of peritonitis in peritoneal dialysis patients. |
| title_full_unstemmed | Proton pump inhibitor use increases the risk of peritonitis in peritoneal dialysis patients. |
| title_short | Proton pump inhibitor use increases the risk of peritonitis in peritoneal dialysis patients. |
| title_sort | proton pump inhibitor use increases the risk of peritonitis in peritoneal dialysis patients |
| url | https://doi.org/10.1371/journal.pone.0224859 |
| work_keys_str_mv | AT sayakamaeda protonpumpinhibitoruseincreasestheriskofperitonitisinperitonealdialysispatients AT makotoyamaguchi protonpumpinhibitoruseincreasestheriskofperitonitisinperitonealdialysispatients AT kunihiromaeda protonpumpinhibitoruseincreasestheriskofperitonitisinperitonealdialysispatients AT naotokobayashi protonpumpinhibitoruseincreasestheriskofperitonitisinperitonealdialysispatients AT naokiizumi protonpumpinhibitoruseincreasestheriskofperitonitisinperitonealdialysispatients AT masaakinagai protonpumpinhibitoruseincreasestheriskofperitonitisinperitonealdialysispatients AT takaakiobayashi protonpumpinhibitoruseincreasestheriskofperitonitisinperitonealdialysispatients AT wataruohashi protonpumpinhibitoruseincreasestheriskofperitonitisinperitonealdialysispatients AT takayukikatsuno protonpumpinhibitoruseincreasestheriskofperitonitisinperitonealdialysispatients AT hironobunobata protonpumpinhibitoruseincreasestheriskofperitonitisinperitonealdialysispatients AT yasuhikoito protonpumpinhibitoruseincreasestheriskofperitonitisinperitonealdialysispatients |